Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma

Background Papillary thyroid carcinoma ( PTC ) is the most common endocrine malignancy. Vascular endothelial growth factor ( VEGF ) is a mediator implicated with cell proliferation, differentiation and migration, and monocyte/macrophage chemotaxis. In present study, we aimed to investigate the relationship between VEGF gene polymorphisms (G+405C, T‐460C, and A‐2578C) and PTC susceptibility. Methods DNA was isolated from peripheral blood leukocytes of 127 patients with PTC and 203 healthy controls. Genotyping was performed by real‐time PCR . Association of genotypes with susceptibility of PTC was analyzed with multivariate logistic regression adjusted for age, gender and smoking status. Results and Conclusion In G+405C polymorphism, the frequencies of C allele (related with increased VEGF production) and combined CG + CC genotype were found to be higher (3.5 and 5‐fold, respectively) among patients with PTC than controls ( P <.001). However, VEGF T‐460C and A‐2578C polymorphisms are not associated with PTC risk. There was no relationship between VEGF polymorphisms and clinical/laboratory parameters of PTC . Haplotype analysis demonstrated that there was a strong linkage disequilibrium ( LD ) between −460/−2578 (D’=.89, r 2 =.79), weak LD between +405/−460 (D’=.422, r 2 =.035), and +405/−2578 (D’=.43, r 2 =.038) locuses. Additionally, the +405/−460/−2578 GTA haplotype was found to be protective, whereas CTA haplotype to be related with increased PTC risk. As a conclusion, we suggest that VEGF G+405C polymorphism is associated with increased risk of PTC .